SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mission to develop transformative ...
Impel Pharmaceuticals (IMPL – Research Report) received a Hold rating and price target from JonesTrading analyst Sean Kim PhD today. The company’s shares opened today at $0.59. According to TipRanks, ...
The recent 16% drop in Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) stock could come as a blow to insiders who purchased US$108k worth of stock at an average buy price of US$10.76 over the past 12 ...
Impel Pharmaceuticals Inc. (IMPL) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $0.79 per share a year ago. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback